Policy Watch: 20 Synthetic Substances Regulatory Updates — May 13, 2026
This update covers synthetic substances regulatory updates 2026 with 20 key DEA scheduling actions. These include synthetic cannabinoids, opioids, and benzodiazepine analogs. The regulatory changes highlight challenges for clinicians managing cannabis…
Policy Watch: 10 Regulatory Updates — April 12, 2026
This April 2026 update covers synthetic cannabinoids Schedule I placement by the DEA, highlighting key regulatory changes. Cannabis clinicians should note the impact on legal treatment options. These regulatory updates clarify distinctions between…
Policy Watch: DEA Scheduling Benzodiazepines and Synthetic Drugs — April 01, 2026
This April 01, 2026 policy watch covers DEA scheduling benzodiazepines 2026 updates impacting cannabis clinical practice. The DEA's placement of several benzodiazepine analogs in Schedule I affects co-prescription protocols. These regulatory changes…
Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I
The temporary placement of bromazolam in Schedule I highlights regulatory efforts to control novel psychoactive substances. This scheduling reflects concerns about bromazolam's abuse potential and lack of accepted medical use. Clinicians should be aware…
Schedules of Controlled Substances: Placement of 2-Methyl AP-237 in Schedule I
The DEA has placed 2-Methyl AP-237, a synthetic opioid, into Schedule I due to its high abuse potential. This synthetic opioid scheduling reflects federal efforts to control emerging drugs rapidly. Clinicians should monitor these developments for…
Understanding Firearms Regulatory Guidance in the Cannabis Context
Firearms regulatory guidance cannabis issues present complex challenges for clinicians. Understanding the legal conflicts between federal firearms laws and state cannabis regulations is essential. This guidance helps ensure patient safety and proper…
Schedules of Controlled Substances: Temporary Placement of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I
Nitazene synthetic opioids such as N-pyrrolidino metonitazene and N-pyrrolidino protonitazene have been temporarily placed in Schedule I. These substances pose significant overdose risks and are emerging threats in illicit drug supplies. Clinicians…